Some studies have demonstrated that combined aberrant activation of PI3K and KEAP1/NRF2 pathways can substantially promote NSCLC development and is often linked with chemotherapy drug resistance 69. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.